DUBLIN, Ohio, October 30, 2017 — Cordis, a Cardinal Health company, today unveiled a comprehensive interventional cardiology portfolio, which now includes two innovative coronary stents -- the TRYTON Side Branch Stent and Medinol’s NIRxcell™, a cobalt-chromium bare metal stent (BMS). Cordis’ cardiology products will be on display (booth #4130) during the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, in Denver.

The recent Cardinal Health agreement with Medinol, a company based in Israel that is dedicated to the science of cardiovascular intervention, gives Cordis exclusive rights to sell Medinol’s coronary stent portfolio in the U.S. Cordis is now selling Medinol’s NIRxcell™ BMS and, upon Medinol receiving U.S. Food and Drug Administration approval, Cordis will also be the exclusive distributor of the EluNIR™ drug-eluting stent (DES). The EluNIR™ DES is currently an investigational device and not approved for commercial use in the U.S.

“The new Medinol agreement, along with the recent launch of the TRYTON Side Branch Stent and two Meril PTCA Balloon Dilatation Catheters, reestablishes Cordis in the U.S. market with a significant interventional cardiology portfolio,” said Peter Van Haur, vice president of North America Sales and Marketing, Cordis. “By adding these new products to our portfolio, we can make the most significant contribution to the healthcare system and deliver innovative products and solutions that our customers and their patients are seeking.”
Medinol has a long, established history in the coronary stent market and has been an innovator for more than 20 years. The unique design of the company’s products, along with its rigorous standards of manufacturing and safety, make the company a leading developer in this space.

Medinol’s NIRxcell™ Bare-Metal Stent and EluNIR™ Drug-Eluting Stent are supported by a large body of clinical data. The NIRxcell™ BMS has been tested on more than 1,000 patients and found highly effective in numerous clinical trials. The EluNIR™ DES has demonstrated excellent results in two randomized clinical trials including more than 2,200 patients treated in the United States, Canada, Europe and Israel. Data from BIONICS, a global pivotal study of 1,919 patients from 76 sites in 8 countries, was submitted to FDA to support U.S. regulatory approval of the EluNIR™ DES for the treatment of patients with narrowing or blockages to their coronary arteries. The EluNIR™ DES is currently an investigational device and not approved for commercial use in the U.S. Medinol recently received CE-mark and other regulatory clearances in Europe for the EluNIR™ stent.

Cardiology Homepage